Jianfei Chen

Dr. Jianfei Chen

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2022 in Cells
Verified
Journal Article
Open access
PDF file
JCJianfei Chen
Jianfei Chen
RWRui Wang
Rui Wang
LZLiu Zhong-liang
Liu Zhong-liang
JFJun Fan
Jun Fan
SLShenglu Liu
Shenglu Liu
XYXiaoli Yang
Xiaoli Yang
Glutamine metabolism is critical both for the proliferation of cancer cells and the activation of CD8T cells to kill cancer cells. We aim to explore the relationship between the glutamine metabolism of CD8T cells and cancer cells and tumor immunity in the tumor microenvironment. In a TCGA cohort, we found that patients with high scores of glutamine-metabolism-related genes showed poor prognoses, and that a high score of glutamine-metabolism-related genes was an independent risk factor for HCC patients. In single-cell RNA-seq data, we found that, in some patients, the glutamine metabolism gene scores of tumor cells were significantly higher than those of CD8T cells, while decreased ratios of CD8-Tef-GZMA and suppressed tumor-killing activity of CD8-Tef-APOC2 were observed. A further genetic dynamics pseudotime analysis suggested that immune remodeling of these two subpopulations was accompanied by metabolic reprogramming. CD8-Tef-APOC2 in the dominant group tended to metabolize exogenous lipids, while the metabolic program of CD8-Tef-GZMA in the nondominant group was characterized by amino acid and endogenous lipid synthesis. In addition, we found that the glutamine metabolism inhibitor JHU083 promoted the proliferation of CD8T cells and improved the efficacy of PD-1 blockers. We proposed a new tool to quantify the glutamine partitioning between tumor cells and CD8T cells, through which the unique immune microenvironment could be identified at the transcriptome level. Furthermore, the simultaneous destruction of the glutamine metabolism in tumor cells and CD8T cells facilitated the enrichment of tumor-infiltrating CD8T cells and enhanced the efficacy of immunotherapy.

31 March 2023 in International Journal of Surgery
Verified
Journal Article
Open access
BGBenjian Gao
Benjian Gao
JCJianfei Chen
Jianfei Chen
YLYongfa Liu
Yongfa Liu
SHShuai Hu
Shuai Hu
RWRui Wang
Rui Wang
BLbo li
bo li
Background: Enhanced recovery after surgery (ERAS), a multidisciplinary and multimodal perioperative care protocol, has been widely used in several surgical fields. However, the effect of this care protocol on patients receiving minimally invasive bariatric surgery remains unclear. This meta-analysis compared the clinical outcomes of the ERAS protocol and standard care (SC) in patients who underwent minimally invasive bariatric surgery. Material and methods: PubMed, Web of Science, Cochrane Library, and Embase databases were systematically searched to identify literature reporting the effects of the ERAS protocol on clinical outcomes in patients undergoing minimally invasive bariatric surgery. All the articles published until 01 October 2022, were searched, followed by data extraction of the included literature and independent quality assessment. Then, pooled mean difference (MD) and odds ratio with a 95% CI were calculated by either a random-effects or fixed-effects model. Results: Overall, 21 studies involving 10 764 patients were included in the final analysis. With the ERAS protocol, the length of hospitalization (MD: −1.02, 95% CI: −1.41 to −0.64, P<0.00001), hospitalization costs (MD: −678.50, 95% CI: −1196.39 to −160.60, P=0.01), and the incidence of 30-day readmission (odds ratio =0.78, 95% CI: 0.63–0.97, P=0.02) were significantly reduced. The incidences of overall complications, major complications (Clavien–Dindo grade ≥3), postoperative nausea and vomiting, intra-abdominal bleeding, anastomotic leak, incisional infection, reoperation, and mortality did not differ significantly between the ERAS and SC groups. Conclusions: The current meta-analysis indicated that the ERAS protocol could be safely and feasibly implemented in the perioperative management of patients receiving minimally invasive bariatric surgery. Compared with SC, this protocol leads to significantly shorter hospitalization lengths, lower 30-day readmission rate, and hospitalization costs. However, no differences were observed in postoperative complications and mortality.

9 November 2021 in Research Square
Verified
Preprint
Open access
PDF file
JCJianfei Chen
Jianfei Chen
ZLZhong-Liang Liu
Zhong-Liang Liu
SSSong Su
Song Su
JFJun Fan
Jun Fan
STShun-De Tan
Shun-De Tan
XYXiao-Li Yang
Xiao-Li Yang
Background: Hepatocellular carcinoma (HCC) is one of the series malignant aggressive disease which shows elusive biological behavior and terrible prognosis. It is inadequate for the single evaluation system such as tumor-node-metastasis (TNM) staging system to predict the overall survival (OS) in HCC patients. Here, we conducted this study to identify prognosis-related genes, so as to form a reliable prognostic assessment model.Results: From three datasets in the GEO database, we identified two hub genes cytoskeleton associated protein 2 (CKAP2) and forkhead box M1 (FOXM1) among 348 differentially expressed genes (DGEs) that were differentially expressed between HCC and normal samples. The function analysis of those DEGs are enriched in cell division process (e.g., mitotic nuclear division, nuclear chromosome segregation) and metabolic process (e.g., organic acid catabolic process). Then, we established a two-gene model, that extremely distinguished the population at risk of liver cancer to high-risk and low-risk and was even viable in the TNM stage i-ii and iii-iv, vascular invasion and non-invasion subgroups (all P<0.05). Next, a nomogram was set out combined with the two hub genes and clinical risk factors, and the predictive power of the nomogram performed more outstanding than the gene expression or clinical parameters alone.Conclusions: Our two-gene-based evaluation system effectively filtered out the high-risk HCC patients, and could potentially be used for clinical decision-making and individualized management of particular HCC patients.